A5005887623- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Immunotherapy and Immune Responses
- Bladder and Urothelial Cancer Treatments
- FOXO transcription factor regulation
- CAR-T cell therapy research
- Ubiquitin and proteasome pathways
- Cancer, Lipids, and Metabolism
- Immune Cell Function and Interaction
- PARP inhibition in cancer therapy
- Extracellular vesicles in disease
- Radiomics and Machine Learning in Medical Imaging
- Cancer Treatment and Pharmacology
- Economic and Financial Impacts of Cancer
- Nanoplatforms for cancer theranostics
- Peptidase Inhibition and Analysis
- Urinary and Genital Oncology Studies
- Protein Degradation and Inhibitors
- Advanced Breast Cancer Therapies
- Pharmaceutical Economics and Policy
- Renal cell carcinoma treatment
- Cancer Research and Treatments
Mayo Clinic
2018-2025
Mayo Clinic in Arizona
2017-2025
The University of Texas at Austin
2024
WinnMed
2017-2024
Mayo Clinic in Florida
2023
Mayo Clinic Hospital
2023
The University of Texas Southwestern Medical Center
2011-2021
Cleveland Clinic
2019
Roche (Switzerland)
2017
The field of theranostics is rapidly advancing, driven by the goals enhancing patient care. Recent breakthroughs in artificial intelligence (AI) and its innovative theranostic applications have marked a critical step forward nuclear medicine, leading to significant paradigm shift precision oncology. For instance, AI-assisted tumor characterization, including automated image interpretation, segmentation, feature identification, prediction high-risk lesions, improves diagnostic processes,...
ADAM10 and ADAM17 expression soluble PD-L1 (sPD-L1) predict poor prognosis in many malignancies, including patients treated with PD-(L)1 inhibitors. The mechanism of production its effects are unknown. Here we uncover a novel ADAM10- ADAM17-mediated resistance to cleave from the surface malignant cells extracellular vesicles. This cleavage produces an active sPD-L1 fragment that induces apoptosis CD8 + T compromises killing tumor by cells. Reduced site protein-to-mRNA ratios outcomes...
Resistance to next-generation anti-androgen enzalutamide (ENZ) constitutes a major challenge for the treatment of castration-resistant prostate cancer (CRPC). By performing genome-wide ChIP-seq profiling in ENZ-resistant CRPC cells we identify set androgen receptor (AR) binding sites with increased AR intensity (ARBS-gained). While ARBS-gained loci lack canonical response elements (ARE) and pioneer factor FOXA1 motifs, they are highly enriched CpG islands unmethylated dinucleotide-binding...
Abstract Retinoblastoma (RB) protein can exert tumor suppressor functions even when it becomes phosphorylated. It is thus essential to understand how phosphorylated RB (p-RB) expression and function are regulated. Here, we demonstrated that RING finger domain TRIM28 bound promoted ubiquitination degradation of CDK4/6-phosphorylated protein. SETDB1, a known binding partner, protected p-RB from through the methylated by its Tudor independent methyltransferase activity. SETDB1 was found be...
745 Background: The combination of EV-P therapy has recently been approved as first-line (1L) for patients with LA/mUC based on the results EV-302 trial. Herein, we report updated from a cohort who received in real world clinical setting. Methods: This retrospective study included (07/2022-08/2024) at Mayo Clinic completed least one cycle EV-P. best overall response (BOR) was evaluated using radiographic imaging and adjudicated complete (CR), partial (PR), stable disease (SD), mixed (MR), or...
Oncology drug prices are a determinant of health disparities in the US and worldwide. Several new therapeutic agents for non-small cell lung cancer (NSCLC) have become available on market over past decade. Although increased competition typically produces lower prices, among brand-name oncology drugs has not resulted prices.To assess price changes class-specific medications used to treat metastatic NSCLC from 2015 2020.This cross-sectional study, conducted August 13, 2015, 2020, data...
Background Trans-acting programmed death-ligand 1 (PD-L1) derives from malignant cells in three known forms. High levels of secreted splice variant PD-L1 (sPD-L1), ADAM10/ADAM17-shed sPD-L1, and PD-L1-positive extracellular vesicles (evPD-L1) each predict poor prognosis limited response to PD-(L)1 checkpoint inhibitors cancer. To our knowledge, no clinical intervention has reduced any these circulating forms PD-L1. Here, we explore therapeutic plasma exchange (TPE) as a treatment reduce...
Outcomes for resistant metastatic castration-resistant prostate cancer (CRPC) are poor. Stereotactic ablative radiotherapy (SABR) induces antitumor immunity in clinical and preclinical studies, but immunologic biomarkers lacking.Eighty-nine patients with oligometastatic CRPC were identified by 11C-Choline-PET (Choline-PET) from August 2016 to December 2019 treated SABR. Prespecified coprimary endpoints 2-year overall survival (OS) PSA progression. Secondary included SABR-treated local...
Myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) is an autoimmune demyelinating rarely associated with malignancy. We report the clinical, MRI, immunopathology, and treatment response in a person MOGAD melanoma.
B7-H3 (CD276) is a transmembrane glycoprotein of the B7 immune checkpoint superfamily that has emerged as promising therapeutic target. To better understand applicability B7-H3-directed therapies, we analyzed 156,791 samples comprising 50 cancer types to interrogate clinical, genomic, transcriptomic, and immunologic correlates mRNA expression. DNA (592-gene/whole-exome) RNA (whole-transcriptome) sequencing was performed from submitted Caris Life Sciences. high versus low expression based on...
Background Many patients use artificial intelligence (AI) chatbots as a rapid source of health information. This raises important questions about the reliability and effectiveness AI in delivering accurate understandable Purpose To evaluate compare accuracy, conciseness, readability responses from OpenAI ChatGPT-4 Google Bard to patient inquiries concerning novel 177 Lu-PSMA-617 therapy for prostate cancer. Materials methods Two experts listed 12 most commonly asked by on therapy. These...
Lurbinectedin has emerged as a potential treatment option for relapsed small cell lung cancer (SCLC). While clinical trials have demonstrated its efficacy and safety, real-world data are limited. This study aimed to evaluate the safety of lurbinectedin in setting, focusing on use second-line agent beyond SCLC patients.
Abstract Molecular mechanisms underlying intratumoral androgenesis and aberrant androgen receptor (AR) activation in prostate cancer remain poorly understood. Here we demonstrate that ectopic expression of the E3 ubiquitin ligase adaptor speckle-type poxvirus zinc finger domain protein (SPOP) stabilizes 17βHSD4. SPOP bound a functional substrate-binding consensus (SBC) motif 315RATST319 17βHSD4 promoted nondegradable K27- K29-linked polyubiquitination The effect was antagonized by serum-...
Acquisition of resistance to phosphatidylinositol 3-kinase (PI3K)/AKT-targeted monotherapy implies the existence common mechanisms independent cancer type. Here, we demonstrate that PI3K/AKT inhibitors cause glycolytic crisis, acetyl-coenzyme A (CoA) shortage, and a global decrease in histone acetylation. In addition, induce drug by selectively augmenting H3 lysine 27 acetylation (H3K27ac) binding CBP/p300 BRD4 proteins at subset growth factor receptor (GF/R) gene loci. occupation these loci...
Metastatic castration-resistant prostate cancer (mCRPC) resistant to androgen receptor signaling inhibitors (ARSI) is often lethal. Liquid biopsy biomarkers for this deadly form of disease remain under investigation, and underpinning mechanisms ill-understood.
<div>AbstractPurpose:<p>Metastatic castration-resistant prostate cancer (mCRPC) resistant to androgen receptor signaling inhibitors (ARSI) is often lethal. Liquid biopsy biomarkers for this deadly form of disease remain under investigation, and underpinning mechanisms ill-understood.</p>Experimental Design:<p>We applied targeted cell-free DNA (cfDNA) sequencing 126 patients with mCRPC from three academic centers separately performed genome-wide cfDNA methylation on 43...
Abstract Immune checkpoint inhibitors (ICI) are effective for advanced melanoma. However, most develop ICI resistance. Tumor-derived soluble PD-L1 (sPD-L1) and other immunosuppressive factors drive We hypothesized that therapeutic plasma exchange (TPE) may remove sPD-L1 from circulation overcome Patients with metastatic ICI-resistant melanoma elevated received radiotherapy to a minority of lesions, TPE, re-challenge. Primary endpoints were adverse events reduction. Secondary included overall...